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Glucocorticoid excess causes insulin resis-
tance and hypertension. Hepatic expression of
PPARa (Ppara) is required for glucocorticoid-
induced insulin resistance. Here we demon-
strate that afferent fibers of the vagus nerve
interface with hepatic Ppara expression to dis-
rupt blood pressure and glucose homeostasis
in response to glucocorticoids. Selective he-
patic vagotomy decreased hyperglycemia, hy-
perinsulinemia, hepatic insulin resistance,
Ppara expression, and phosphoenolpyruvate
carboxykinase (PEPCK) enzyme activity in
dexamethasone-treated Ppara+/+ mice. Selec-
tive vagotomy also decreased blood pressure,
adrenergic tone, renin activity, and urinary
sodium retention in these mice. Hepatic recon-
stitution of Ppara in nondiabetic, normotensive
dexamethasone-treated PPARa null mice in-
creased glucose, insulin, hepatic PEPCK en-
zyme activity, blood pressure, and renin activity
in sham-operated animals but not hepatic-
vagotomized animals. Disruption of vagal af-
ferent fibers by chemical or surgical means
prevented glucocorticoid-induced metabolic
derangements. We conclude that a dynamic
interaction between hepatic Ppara expression
and a vagal afferent pathway is essential
for glucocorticoid induction of diabetes and
hypertension.
INTRODUCTION
Insulin resistance, a potentially lethal metabolic disorder
associated with diabetes, hypertension, and vascular
disease, is poorly understood. Glucocorticoid excess,
whether caused by exogenous administration, endoge-
nous overproduction associated with Cushing’s syn-Celdrome, or accelerated conversion of inactive to active glu-
cocorticoids in tissues (Masuzaki et al., 2001; Paterson
et al., 2004), alters lipid metabolism and produces insulin
resistance. Given the phenotypic similarities between
glucocorticoid excess and insulin resistance caused by
diet-induced obesity, defining how glucocorticoids cause
insulin resistance is likely to be relevant to common
obesity-related diseases like diabetes and hypertension.
In mice, the development of diabetes and hypertension
following chronic glucocorticoid exposure requires ex-
pression of the lipid-activated transcription factor PPARa
in liver (Bernal-Mizrachi et al., 2003).
A member of the nuclear receptor superfamily (Berger
and Moller, 2002), PPARa orchestrates the adequate pro-
vision of substrates for critical tissues such as the central
nervous system (CNS) in response to prolonged fasting.
PPARa activation promotes fatty-acid oxidation (Reddy,
2001), ketogenesis (Rodriguez et al., 1994), and gluconeo-
genesis (Bernal-Mizrachi et al., 2003; Koo et al., 2004;
Patsouris et al., 2004). Fasted mice that are deficient in
PPARa develop hypoglycemia and fatty liver (Kersten
et al., 1999). The same phenotype develops in PPARa
wild-type mice when deprived of dietary and synthesized
fat (Chakravarthy et al., 2005), highlighting the role of lipid
in activation of the receptor. Physiological responses me-
diated by PPARa, like those occurring with fasting in the
short-term, may become pathophysiological in the setting
of long-term stressors such as obesity and glucocorticoid
exposure. Consistent with this notion, two independent
groups have reported that PPARa deficiency prevents
glucose intolerance caused by diet-induced obesity
(Guerre-Millo et al., 2001; Tordjman et al., 2001).
Maladaptive PPARa signaling is not limited to effects on
glucose metabolism. PPARa deficiency also protects
mice from hypertension induced by either high-fat feeding
(Tordjman et al., 2001) or glucocorticoids (Bernal-Mizrachi
et al., 2003), suggesting that chronic activation of PPARa
in mice initiates a cascade of events resulting in several
detrimental components of insulin resistance. Species
differences between mice and humans in terms of PPARa
biology could limit the relevance of these mouse studies
to human disorders. However, recent data indicate thatl Metabolism 5, 91–102, February 2007 ª2007 Elsevier Inc. 91
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Vagally Mediated Insulin ResistanceFigure 1. Selective Hepatic Vagotomy Reverses Glucocorticoid-Induced Insulin Resistance
(A) Operative field for selective nerve interruption. The liver is visible in the upper left quadrant. The esophagus, ventral trunk of the vagus nerve, and
hepatic branch of the vagus are denoted by arrows.
(B) Body weight before and after selective hepatic vagotomy or sham surgery. Ppara+/+ mice were treated with Dex for 5 months (1 mg/kg i.p. every
other day) and then underwent either selective hepatic vagotomy or sham surgery. Weight data in grams are presented for ten mice in each group
around the time of the surgery. Weeks on the horizontal axis are not to scale and represent time before and after surgery, which is indicated as ‘‘Sx.’’
(C) Glucose tolerance testing (i.p. administration of 1 g/kg D-glucose to fasted mice at time 0 followed by blood glucose measurements) in Ppara+/+
(n = 13) and Ppara/ (n = 13) mice after 5 months of treatment with Dex.
(D) Glucose tolerance testing in Ppara+/+ mice treated with Dex as in Figure 1C and then randomized to either selective hepatic vagotomy (n = 7, open
symbols) or sham surgery (n = 6, closed symbols).
(E) Glucose tolerance testing in Ppara/ mice treated with Dex as in Figure 1C and then randomized to either selective hepatic vagotomy (n = 5, open
symbols) or sham surgery (n = 5, closed symbols).92 Cell Metabolism 5, 91–102, February 2007 ª2007 Elsevier Inc.
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Vagally Mediated Insulin ResistancePPARa activation in normal humans increases blood pres-
sure (Subramanian et al., 2006), results that complement
mouse studies implicating PPARa in blood pressure con-
trol. Exactly how PPARa activation affects both blood
pressure and glucose is unknown.
The CNS integrates signals from peripheral sites like the
liver to modulate blood pressure and glucose. Infusion of
long-chain fatty acids into the portal vein, a major conduit
to the liver, has effects that suggest involvement of the
CNS including increases in circulating levels of epineph-
rine and norepinephrine, elevated blood pressure, and ac-
celerated hepatic glucose production (Benthem et al.,
2000; Grekin et al., 1995, 1997). Hepatic signals are likely
transmitted to the CNS by the vagus nerve since vagal ac-
tivity is increased by portal or jejunal infusion of lipids
(Randich et al., 2001). To test the hypothesis that the
vagus nerve mediates PPARa-dependent metabolic dys-
function induced by glucocorticoids, we studied the
effects of selective hepatic branch vagotomy in Ppara+/+
and Ppara/ mice as well as the effects of selective dis-
ruption of vagal afferents following chronic dexametha-
sone therapy.
RESULTS
Selective Hepatic Vagotomy Reverses
Insulin Resistance
In a series of experiments, Ppara+/+ (n = 37) and Ppara/
(n = 37) mice were treated with dexamethasone (Dex)
(1 mg/kg) by i.p. injection every other day for 5 months,
followed by selective hepatic vagal nerve sectioning in Dex-
treated Ppara+/+ mice (n = 20) and Dex-treated Ppara/
mice (n = 20). An intraoperative photograph demonstrat-
ing the isolation of the hepatic branch of the vagus nerve
is shown in Figure 1A. As a control, sham surgery (isolation
of the nerve without resection) was performed on Dex-
treated Ppara+/+mice (n = 17) and Dex-treated Ppara/
mice (n = 17). As an additional control, separate cohorts
of Ppara+/+ (n = 26) and Ppara/ (n = 20) animals were
treated with normal saline instead of Dex. Saline-treated
mice also underwent either selective hepatic vagotomy
or the sham procedure. Interventions were performed in
five sequential experiments, each yielding the same re-
sults. Consistent with previous results (Bernal-Mizrachi
et al., 2003), there was no effect of chronic Dex treatment
on body weight in either genotype (see Figures S1A and
S1B in the Supplemental Data available with this article
online). Metabolic studies were performed 3 weeks after
surgery when animals recovered their body weight (Fig-
ure 1B) and food intake had returned to normal (Fig-
ure S1C). Serum levels of alanine aminotransferase,Cela marker of liver inflammation, were normal 3 weeks after
surgery (data not shown).
As expected (Bernal-Mizrachi et al., 2003), fasting levels
of glucose and insulin were higher in Dex-treated Ppara+/+
mice as compared to Dex-treated Ppara/ mice (Table
S1). There were no differences between genotypes in cho-
lesterol, NEFA, triglycerides, body weight, or body com-
position at baseline or with Dex (Table S1). Dex-treated
Ppara+/+ mice had higher glucose levels during glucose
tolerance testing as compared to Dex-treated Ppara/
mice (Figure 1C). This glucose intolerance in Dex-treated
Ppara+/+ mice was abolished by selective hepatic vagot-
omy, but not by sham surgery (Figure 1D). Glucose toler-
ance was unaffected by either procedure in Dex-treated
Ppara/ animals (Figure 1E). Fasting insulin levels were
lower in Ppara+/+ animals after vagotomy as compared
to sham surgery, but there were no effects on serum
chemistries, body composition, or glucagon levels (Table
S2). Insulin levels at 30 min during glucose tolerance test-
ing were also lower in vagotomized as compared to sham-
operated Dex-treated Ppara+/+ mice (0.33 ± 0.07 versus
0.70 ± 0.09 ng/ml; p = 0.04). Dex-treated Ppara+/+ mice
became less hypoglycemic than Dex-treated Ppara/
animals during insulin tolerance testing, indicating insulin
resistance (Figure 1F). Vagotomy resulted in greater
insulin responsiveness during insulin tolerance testing in
Dex-treated Ppara+/+ mice as compared to sham surgery
(Figure 1G). These effects of enhanced insulin sensitivity
following vagotomy persisted for at least 3 months after
surgery (data not shown). Vagotomy had no effect in
Ppara/ mice (Figure 1H). Chronic saline injections had
no effect on fasting serum chemistries and glucose or in-
sulin tolerance testing in either genotype (data not shown).
Vagotomy Effects on Glucose Production
and Ppara Expression
In hyperinsulinemic-euglycemic clamp experiments per-
formed 6 weeks after surgery, endogenous glucose pro-
duction was suppressed to a greater degree by insulin in
vagotomized as compared to sham-operated Dex-treated
Ppara+/+ mice (Figure 2C, left bars). There was no effect
of vagotomy on saline-treated Ppara+/+ mice (Figure 2C,
right bars). There were no significant effects on peripheral
insulin sensitivity as measured by the clamp-determined
rate of glucose disposal (Figure 2B). Enzyme activity for
PEPCK, a key enzyme in gluconeogenesis, was 42%
lower in the livers of vagotomized Dex-treated mice as
compared to sham-operated mice (Figure S2A). Taken to-
gether, these results suggest that interruption of vagal
nerve signaling blocks Dex-induced glucose intolerance
in part by decreasing gluconeogenesis.(F) Insulin tolerance testing (injection of fasted mice with 0.75 U/kg insulin at time 0 followed by blood glucose measurements) for the animals in
Figure 1C.
(G) Insulin tolerance testing for the animals in Figure 1D.
(H) Insulin tolerance testing for the animals in Figure 1E. In this and all other figures, results are presented as mean ± SEM. *p < 0.05 at the same time
point by two-tailed, unpaired t test. Panels show results from representative experiments. Similar results were seen in at least three independent
experiments with different cohorts of mice.l Metabolism 5, 91–102, February 2007 ª2007 Elsevier Inc. 93
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Vagally Mediated Insulin ResistanceFigure 2. Effects of Vagotomy on Insulin Sensitivity, Hepatic Gene Expression, and Reconstitution of PPARa in Ppara/ Mice
(A–C) Hyperinsulinemic-euglycemic clamp data from Ppara+/+ mice after chronic treatment with Dex followed by selective hepatic vagotomy (n = 5) or
sham surgery (n = 5) (left side of each panel) and after chronic treatment with saline followed by hepatic vagotomy (n = 4) or sham surgery (n = 4) (right
side of each panel).
(D–F) Expression of Ppara and the known PPARa target genes Acox and Acadam in liver. RNA was analyzed by semiquantitative RT-PCR. Samples
were isolated from Ppara+/+ mice treated chronically with Dex and then subjected to selective hepatic vagotomy (n = 4) or sham surgery (n = 4).
(G) Glucose tolerance testing in Dex-treated mice. Ppara/ mice were treated chronically with Dex followed by selective hepatic vagotomy (n = 7) or
sham surgery (n = 7). After recovery from surgery,Ppara+/+ expression was reconstituted in liver (as documented by RT-PCR; see below), and glucose
tolerance testing was performed.
(H) Glucose tolerance testing in saline-treated mice. Ppara/ mice were treated chronically with saline followed by selective hepatic vagotomy (n = 5)
or sham surgery (n = 4). After recovery from surgery, Ppara+/+ expression was reconstituted in liver, and glucose tolerance testing was performed.
Results are presented as mean ± SEM. *p < 0.05 by two-tailed, unpaired t test except for in Figure 2C, where ANOVA was used.
(I) Tissue survey of gene expression by RT-PCR following treatment with the PPARa adenovirus. Lane 1, water control; lane 2, whole brain; lane 3,
brainstem; lane 4, hypothalamus; lane 5, liver; lane 6, heart; lane 7, lung.94 Cell Metabolism 5, 91–102, February 2007 ª2007 Elsevier Inc.
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Vagally Mediated Insulin ResistanceSelective hepatic vagotomy decreased Ppara expres-
sion in the liver, providing a potential mechanism for ob-
served effects on glucose metabolism. Hepatic Ppara ex-
pression was 6-fold lower in vagotomized Dex-treated
animals as compared to sham-operated Ppara+/+ animals
(Figure 2D). Messenger RNA levels for acyl-CoA oxidase
(Acox) and medium-chain acyl-CoA dehydrogenase (Aca-
dam), known PPARa target genes, were decreased in
vagotomized as compared to sham-operated mice (Fig-
ures 2E and 2F), but there was no effect on the expression
of the coactivator PGC-1a (Ppargc1), another modulator
of gluconeogenesis (data not shown).
Reconstitution of Hepatic Ppara Expression
When Ppara expression was reconstituted in the livers of
normoglycemic Dex-treated Ppara/ mice subjected to
either vagotomy or sham surgery (see metabolic charac-
teristics of these mice in Figures 1E and 1H), sham-
operated animals had greater glucose excursions than
vagotomized mice during glucose tolerance tests (Fig-
ure 2G). At 30 min after glucose injection, insulin levels
were 3-fold higher in sham-operated as compared to va-
gotomized animals (0.9 ± 0.2 versus 0.3 ± 0.06 ng/ml;
p < 0.04). Enzyme activity for PEPCK was 75% lower
in vagotomized Dex-treated Ppara/ mice reconstituted
with AdPPARa as compared to sham-operated animals
treated with the same virus (Figure S2B). There was no ef-
fect on the glycemic response (Figure 2H) or insulin levels
(data not shown) when Ppara expression was reconsti-
tuted in the livers of saline-treated mice. Treatment with
control virus has no effect in this model (Bernal-Mizrachi
et al., 2003). PPARa protein has been detected in the
CNS (Moreno et al., 2004), raising the possibility that cen-
tral activation of this receptor affects responses in our
model. However, AdPPARa treatment of Dex-treated
PPARa null mice produces glucose intolerance associ-
ated with Ppara expression in liver but not whole brain,
brainstem, or hypothalamus (or other tissues; Figure 2I).
These data suggest that hepatic expression of Ppara
(but not CNS Ppara expression) and an intact hepatic va-
gus nerve are required for the development of glucocorti-
coid-induced insulin resistance.
Intact Vagus Nerve Is Required
for Dex-Induced Hypertension
With Dex treatment, both systolic and diastolic blood
pressure was20 mm Hg higher in Ppara+/+ as compared
to Ppara/ mice (Figure 3A, left panel). Selective hepatic
vagotomy in Dex-treated Ppara+/+ mice decreased sys-
tolic blood pressure by 10 mm Hg (p < 0.001) and diastolic
pressure by 9 mm Hg (p < 0.01) (Figure 3A, middle panel).
These differences detected by tail-cuff determinations
were confirmed invasively in anesthetized mice (Fig-
ure S3A). There was no effect of vagotomy on blood pres-
sure in Dex-treated Ppara/ mice (Figure 3A, right panel)
or in saline-treated mice of either genotype (Figure 3B).
Blood pressure measurements were made 3 weeks after
surgery when there was no difference between vagotom-
ized and sham-operated mice in sodium intake, water in-Cetake, or urine output (Figures S1D, S1F, and S1G). Plasma
renin activity and urinary catecholamine levels, critical de-
terminants of renal sodium handling and blood pressure,
decreased by 50% in Dex-treated Ppara+/+ mice after
vagotomy compared with sham-operated animals (Table
1). Urinary sodium excretion increased 3-fold after vagot-
omy in Dex-treated Ppara+/+ mice (Table 1), consistent
with less activity of the sympathetic nervous system and
renin-angiotensin-aldosterone axis after selective hepatic
vagotomy. There were no effects on serum leptin.
Reconstitution of Hepatic Ppara Expression
and Blood Pressure
Reconstitution of Ppara expression in the livers of normo-
tensive Dex-treated Ppara/ mice subjected to either
vagotomy or sham surgery by infusion of a PPARa
adenovirus increased systolic blood pressure by 25 mm
Hg (p = 0.001) and diastolic blood pressure by 16 mm
Hg (p = 0.04) in sham-operated animals compared to
vagotomized animals (Figure 3C). Blood pressure effects
were confirmed invasively (Figure S3B). There was no
effect on blood pressure in saline-treated mice (Figure 3D).
Hepatic reconstitution of Ppara in sham-operated animals
nearly doubled plasma renin activity (p = 0.04) and de-
creased urinary sodium (p = 0.04) as compared to
vagotomized mice treated with the PPARa adenovirus
(Table S3). These data suggest that hepatic Ppara activa-
tion and the presence of an intact vagus nerve promote
glucocorticoid-induced hypertension through a renin-
dependent mechanism.
Selective Disruption of Vagal Afferent Fibers
Since both afferent (Uno et al., 2006) and efferent (Lam
et al., 2005) fibers of the vagus have been implicated in
systemic metabolic effects, vagal afferents were selec-
tively disrupted using two independent techniques in ani-
mals treated with Dex. Hepatic vagal branch application of
capsaicin, which is toxic to unmyelinated afferent fibers,
disrupted vagal afferent fibers (Figures 4C and 4D, arrows)
but did not affect myelinated fibers (Figures 4C and 4D, ar-
rowheads) as demonstrated by electron microscopy 10
days following the procedure. Unmyelinated fibers from
vehicle-treated vagus nerves were unaffected (Figure 4A,
arrows), as were fibers in the posterior vagal trunk (which
was untreated) of animals subjected to capsaicin treat-
ment of the hepatic vagal branch (Figure 4B). There was
no difference in food intake between capsaicin- and con-
trol-treated mice 10 days after the procedure (Figure 4E)
and no difference in weight (Figure 4F). Capsaicin-induced
disruption of vagal afferent fibers reversed glucose intoler-
ance (Figure 4G). To confirm this observation, vagal affer-
ents were surgically interrupted at the brainstem. Repre-
sentative views of the surgical approach are shown in
Figures 5A–5C, with the area denoted by the rectangle in
Figure 5A expanded in Figure 5B and the area denoted
by the rectangle in Figure 5B expanded in Figure 5C.
Body weights following the central afferent vagotomy
and the sham procedure (in which the dura was opened
and the field visualized without surgical resection) arell Metabolism 5, 91–102, February 2007 ª2007 Elsevier Inc. 95
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Vagally Mediated Insulin ResistanceFigure 3. Effects of Vagotomy on Blood
Pressure
(A) Ppara+/+ and Ppara/ mice were treated
with Dex for 5 months (1 mg/kg i.p. every other
day), and systolic (SBP) and diastolic (DBP)
blood pressure was determined by tail cuff
(left panel; n = 13 for each genotype). Mice
then underwent either selective hepatic vagot-
omy or sham surgery, and blood pressure
measurements were repeated following recov-
ery in Ppara+/+ (middle panel; n = 14 for vagot-
omy, n = 10 for sham surgery) and Ppara/
(right panel; n = 14 for vagotomy, n = 8 for
sham surgery) mice. The blood pressure ef-
fects in Ppara+/+ mice were confirmed inva-
sively (see Figure S3).
(B) Ppara+/+ and Ppara/mice were treated
with normal saline injections for 5 months,
and systolic (SBP) and diastolic (DBP) blood
pressure was determined by tail cuff (left panel;
n = 10 for each genotype). These control mice
then underwent either selective hepatic vagot-
omy or sham surgery, and blood pressure
measurements were repeated following recov-
ery in Ppara+/+ (middle panel; n = 5 for vagot-
omy, n = 5 for sham surgery) and Ppara/
(right panel; n = 5 for vagotomy, n = 5 for
sham surgery) mice.
(C)Ppara/ mice were treated chronically with
Dex followed by selective hepatic vagotomy
(n = 7) or sham surgery (n = 7). After recovery
from surgery, Ppara+/+ expression was recon-
stituted in liver (as documented by RT-PCR),
and blood pressure was measured by tail cuff
(shown here) and confirmed invasively (shown
in Figure S3).
(D) Ppara/ mice were treated chronically with
saline followed by selective hepatic vagotomy
(n = 5) or sham surgery (n = 5). After recovery
from surgery, Ppara+/+ expression was recon-
stituted in liver, and blood pressure was mea-
sured. Results are presented as mean ±
SEM. *p < 0.05 by two-tailed, unpaired t test.shown in Figure 5D. Three weeks after the surgeries, cen-
tral afferent vagotomy lowered blood pressure (Figure 5E)
and improved glucose tolerance (Figure 5F) in Dex-treated
mice.
DISCUSSION
Despite important anti-inflammatory properties, glucocor-
ticoids are potentially dangerous due to side effects that
include insulin resistance, diabetes, and hypertension.
Here we show that glucocorticoid-induced glucose intol-
erance and elevated blood pressure depend on an affer-
ent vagal nerve pathway initiated by expression of the
lipid-activated transcription factor PPARa in the liver.
Several lines of evidence implicate the autonomic ner-
vous system in the regulation of hepatic metabolism, al-
though results vary based on the experimental model. In
dogs, chronic denervation of the liver has little effect on
glucose metabolism (Wada et al., 1995), while acute dis-
ruption of the vagus decreases hepatic glucose produc-96 Cell Metabolism 5, 91–102, February 2007 ª2007 Elsevier Ition by inhibiting glycogenolysis (Cardin et al., 2002). In
rats, both vagotomy (Xie and Lautt, 1996; Matsuhisa
et al., 2000) and electrical stimulation of the vagus (Peitl
et al., 2005) have been reported to induce insulin resis-
tance. Also in rats, the hypothalamic infusion of fatty acids
suppresses hepatic glucose production through mecha-
nisms involving descending vagal input (Lam et al.,
2005). Adenoviral expression of PPARg2 in liver de-
creases peripheral adiposity in a process that depends
on the afferent vagus (Uno et al., 2006). By extending
selective hepatic vagotomy and disruption of the afferent
vagus to mice with genetic manipulations of PPARa, there
are three conclusions we can make about the role of the
vagus nerve in metabolism.
First, an intact hepatic branch of the vagus in the pres-
ence of hepatic Ppara expression is required for the devel-
opment of glucocorticoid-induced diabetes. Vagotomy
reversed hyperglycemia in Ppara+/+ mice (Figure 1D),
and reconstitution of Ppara expression in the livers of
Dex-treated Ppara/ mice induced hyperglycemia afternc.
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Vagally Mediated Insulin ResistanceTable 1. Effects of Selective Hepatic Vagotomy versus Sham Surgery in Dex-Treated Ppara+/+ and Ppara/ Mice
Ppara+/+
p
Ppara/
pSham Vagotomy Sham Vagotomy
Renin (ng/ml/hr) 22.5 ± 3.4 (n = 8) 14 ± 2.2 (n = 8) 0.01 23 ± 4.0 (n = 8) 18.2 ± 1.2 (n = 8) 0.3
Urinary norepinephrine
(ng/day)
530 ± 84 (n = 8) 272 ± 71 (n = 8) 0.03 267 ± 48 (n = 8) 186 ± 50 (n = 8) 0.4
Urinary sodium
(nmol/mg Cr/g/day)
0.07 ± 0.01 (n = 7) 0.11 ± 0.01 (n = 9) 0.01 0.07 ± 0.01 (n = 7) 0.09 ± 0.01 (n = 12) 0.3
Leptin (pg/ml) 4.08 ± 1.3 (n = 5) 5.1 ± 1.9 (n = 5) 0.6 6.2 ± 0.5 (n = 5) 5.4 ± 1.2 (n = 5) 0.5
Ppara+/+ and Ppara/ mice were treated with Dex for 5 months (1 mg/kg i.p. every other day) and then subjected to either selective
hepatic vagotomy or sham surgery. Dex-induced elevated blood pressure was corrected by vagotomy inPpara+/+ mice as shown in
Figure 3. At the time of blood pressure measurement, plasma renin activity as well as serum leptin was measured, and 24 hr urine
collections were obtained and assayed for norepinephrine and sodium. Results are presented as mean ± SEM.sham surgery but not after vagotomy (Figure 2G). PPARa
was not a passive participant in this process. Glucocorti-
coids are known to induce hepatic Ppara gene expression
(Lemberger et al., 1994, 1996), and Ppara is an important
mediator of gluconeogenesis (Bernal-Mizrachi et al.,
2003; Koo et al., 2004). Surprisingly, selective hepatic
vagotomy decreased hepatic Ppara expression and the
expression of two PPARa target genes,Acox and Acadam
(Figures 2D–2F), without affecting expression of the co-
activator Ppargc1. These findings, occurring in weight-
stable mice with normal food intake and no evidence of
hepatic dysfunction, suggest that vagal input is critical
for the maintenance of glucocorticoid-induced transcrip-
tional responses in the liver.
Rossetti and colleagues recently provided evidence for
links between the CNS and hepatic glucose production
(Obici et al., 2002) involving the hepatic branch of the
vagus (Lam et al., 2005). Our data show that selective
hepatic vagotomy has no effect on glucose production
in saline-treated wild-type mice (Figure 2). This procedure
also had no effect on glucose production in saline-treated
rats (see Supplementary Figure 3 in Lam et al., 2005). Lam
et al. showed that an Intralipid/heparin infusion decreases
glucose production through vagal efferents. The current
study shows that glucocorticoid treatment increases glu-
cose production through vagal afferents. Collectively, the
results indicate that the vagus can mediate increased or
decreased hepatic glucose production through different
fibers depending on the specific stimulus.
The second conclusion we can make is that an intact
hepatic branch of the vagus in the presence of hepatic
Ppara expression is required for the development of glu-
cocorticoid-induced hypertension. Vagotomy reversed
established blood pressure elevations in Ppara+/+ mice
(Figure 3A) in concert with lower catecholamines, de-
creased renin activity, and less sodium retention (Table
1). Reconstitution of Ppara expression in the livers of
Dex-treated Ppara/ mice elevated blood pressure after
sham surgery, but not after vagotomy (Figure 3C). Consis-
tent with the current results, glucocorticoid-induced hy-
pertension is thought to be caused by increased sodium
retention (Whitworth et al., 1979). The pathophysiologyCemay also involve enhanced vascular reactivity to pressors
(Walker et al., 1994) and altered vascular nitric oxide pro-
duction (Wallerath et al., 1999). Our data point to a critical
role of an intact vagus nerve responding to hepatic Ppara
expression in mediating the blood pressure response to
chronic glucocorticoid exposure.
Our third conclusion is that intact vagal afferent fibers
are required for glucocorticoid-induced glucose intoler-
ance and hypertension. In animals treated with Dex, dis-
ruption of the afferent vagus using topical application of
the selective neurotoxin capsaicin (Figure 4) reversed glu-
cose tolerance (Figure 4G). Surgical interruption of vagal
afferents at the brainstem (Figure 5) reversed glucose in-
tolerance (Figure 5F) and lowered blood pressure (Fig-
ure 5E). These surgical results should be interpreted with
the caveat that, although physiological effects resembled
those with capsaicin, neuroanatomical verification as
presented in the rat model (Walls et al., 1995) was not
performed in these mice. Hepatic expression of a different
nuclear receptor, PPARg2, also appears to require intact
vagal afferents to produce systemic effects, but these ef-
fects are strikingly different from those induced by PPARa:
induction of hepatic expression of PPARg2 increases in-
sulin sensitivity (Uno et al., 2006), while Dex induction of
hepatic expression of PPARa in the current study de-
creases insulin sensitivity. The fact that afferent vagal fi-
bers are involved in both suggests that metabolic signals
sent by each nuclear receptor in the liver are distinct.
While neuroanatomical data for the vagus in mice are lim-
ited, rat studies indicate that sensory vagal fibers do not
appear to provide substantial direct innervation of hepato-
cytes, instead tracking with portal triads in proximity to
branches of the hepatic artery, portal vein, and bile ducts
(Berthoud and Neuhuber, 2000). It is plausible that meta-
bolic responses involve a regulatory compartment of he-
patocytes located near portal triads. Since there may be
little direct innervation of hepatocytes by the vagus, induc-
tion of PPARa-dependent genes in these cells could
increase extracellular metabolites in the portal triad, re-
sulting in vagal afferent signals ultimately translated by
the brain into peripheral effects that include glucose intol-
erance and hypertension. Clarifying the nature of thesell Metabolism 5, 91–102, February 2007 ª2007 Elsevier Inc. 97
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Vagally Mediated Insulin ResistanceFigure 4. Selective Peripheral Afferent Vagal Denervation Reverses Dex-Induced Insulin Resistance
Dex-treated Ppara+/+ mice underwent either capsaicin or vehicle application to the hepatic vagal branch. Electron microscopy (EM) of hepatic vagal
nerve sections (A–D) and physiological studies (E–G) were performed 10 days later. In (A)–(D), arrows represent unmyelinated fibers and arrowheads
represent myelinated fibers.
(A) EM assessment of the vagus in vehicle-treated mice.
(B) EM evaluation from the posterior vagal trunk of an animal subjected to capsaicin treatment of the hepatic vagal branch.
(C and D) EM of hepatic vagal nerves from two different capsaicin-treated animals.
(E) Food intake in grams per day from four animals in each group.
(F) Body weight after capsaicin or vehicle treatment. Weight data in grams are presented for five mice in each group. The horizontal axis represents
days after the surgical procedure.
(G) Glucose tolerance testing in capsaicin-treated (n = 5) and vehicle-treated (n = 5) mice. Results are presented as mean ± SEM. *p < 0.05 at the same
time point by two-tailed, unpaired t test. Panels show results from representative experiments. Similar results were seen in two independent exper-
iments with different cohorts of mice.PPARa-dependent metabolites and the characteristics of
the vagal afferent signals they generate could yield new
approaches for treating insulin resistance.
The vagus nerve derives its name from the Latin word for
‘‘wanderer,’’ a reference to the meandering anatomic dis-
tribution of the nerve. Given recent discoveries that this
nerve suppresses inflammation (Borovikova et al., 2000),98 Cell Metabolism 5, 91–102, February 2007 ª2007 Elsevier Ininhibits seizure activity (Uthman et al., 2004) and depres-
sion (Nahas et al., 2005), modulates CNS responses to
fatty acids (Lam et al., 2005), and establishes a circuit be-
tween the liver and CNS leading to either enhanced insulin
sensitivity (Uno et al., 2006) or diabetes and hypertension
(the current work), it appears that the full extent of the
nomadic journey of the vagus is still unknown.c.
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Vagally Mediated Insulin ResistanceFigure 5. Central Afferent Vagal Nerve Sectioning Reverses Dex-Induced Hypertension and Insulin Resistance
Dex-treated Ppara+/+ mice were randomly assigned to either selective section of the vagal afferent fibers in the brainstem or a sham operation.
(A–C) Views of the operative field, with the area enclosed by the rectangle in (A) expanded in (B) and the rectangle in (B) expanded in (C).
(D) Body weight in grams is presented for three mice in each group. The horizontal axis represents weeks after the surgical procedure.
(E) Tail-cuff systolic (SBP) and diastolic (DBP) blood pressure was obtained 3 weeks after the procedure (n = 3 for each group).
(F) Glucose tolerance testing 3 weeks after central afferent vagal sectioning (n = 3) and the sham operation (n = 3). Results are presented as mean ±
SEM. *p < 0.05 at the same time point by two-tailed, unpaired t test.EXPERIMENTAL PROCEDURES
Animals
The Ppara+/+ and Ppara/ mice used for these studies were produced
by crossing Ppara/ animals (a kind gift from Dr. Frank Gonzalez and
developed at the NIH as described by Lee et al., 1995) with inbred
C57BL/6 animals to the N6 generation. Littermate mice of both sexes
were treated with either Dex (1 mg/kg i.p.) or an equal volume of normal
saline every other day beginning at the age of 8 weeks. The same ef-
fects of interventions were seen in both sexes. Animals were housed
in a specific-pathogen-free barrier facility with free access to water
and standard mouse chow (providing 6% of calories as fat). The Wash-
ington University Animal Studies Committee approved these experi-
ments, and all procedures were performed as recommended by the
NIH Guide for the Care and Use of Laboratory Animals and the Labo-
ratory Animal Welfare Act.
Selective Hepatic Vagotomy
Vagotomy was performed by modifying a procedure previously de-
scribed in rats (Bellinger and Williams, 1981). Mice were anesthetized
with pentobarbital (60 mg/kg). The abdominal wall was incised at mid-
line, the stomach was pulled down, and the ligaments attaching the
liver to the stomach were severed. The anterior ligament and the mem-
branous connection of the left lobe of the liver to the diaphragm were
cut to give better visibility of the esophageal-hepatic attachments. ThisCeregion contains a neurovascular bundle including the hepatic branch of
the vagus nerve. This branch was selectively ligated by silk sutures and
cauterized (Smith and Jerome, 1983). The tissue at the ligation site was
resected and examined microscopically to ensure that the manipu-
lated structure represented nerve. After experiments, animals were
sacrificed and the adequacy of the procedure was assessed by dem-
onstrating the absence of vagal nerve tissue between the silk sutures
and by tracing the nerve remnant to its origin in the neck by dissection.
Selective Disruption of Vagal Afferents
Two independent techniques, topical application of capsaicin and sur-
gical interruption of fibers at the brainstem, were used to disrupt vagal
afferents.
Capsaicin (10 mg) was sonicated with 0.1 ml Tween 80 for 10 min
and brought to 1 ml with olive oil. Following induction of pentobarbital
anesthesia, the hepatic vagal nerve was exposed as noted above.
Gauze soaked in capsaicin, isolated from surrounding tissues by par-
affin paper, was wrapped around the nerve for 30 min, with additional
agent applied twice during that period to yield a total dose of 0.5 mg
per mouse. Tween 80 in olive oil was applied to the nerve in control
animals. Physiological evaluations were conducted 10 days after
surgery.
Surgical interruption of the afferent fibers at the left side of the
brainstem was performed using a dorsolateral approach. Unilateral
sectioning was pursued due to the technically demanding nature ofll Metabolism 5, 91–102, February 2007 ª2007 Elsevier Inc. 99
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Vagally Mediated Insulin Resistancethe procedure and because previous data in rats indicate that the he-
patic vagus projects predominantly to the left side of the brainstem
(Magni and Carobi, 1983; Berthoud et al., 1992). Following induction
of anesthesia with ketamine (75 mg/kg) and medetomidine (1 mg/kg,
i.p.), the head and dorsal surface of the upper thorax were shaved
and swabbed with Betadine, the eyes were protected with artificial
tears, and the animal was secured into a stereotaxic device. Temper-
ature was maintained using a heating pad and a heat lamp attached to
a temperature probe. Muscles attached to the occipital portion of the
skull were resected to expose the foramen magnum. Fine-tipped for-
ceps were used to cut through the ventrolateral aspect of the skull ros-
trally to expose the brainstem. Care was necessary to avoid breaching
the venous sinus near the rostral end of the brainstem. The brainstem
was gently retracted to allow visualization of the vagus nerve between
where it attaches to the brainstem and where it exits the skull through
the posterior lacerated foramen. The dura was opened using iridec-
tomy scissors to visualize the posterior cranial nerves. When the root-
lets of the vagus were identified, the dorsal rootlets were avulsed from
the brainstem using a dura hook inserted between the dorsal (afferent)
and ventral (efferent) rootlets. After deafferentation, artificial dura
(Duragen) was applied to the exposed area. Muscles were sutured
back onto their insertion points on the skull, and the skin was closed.
The animals were removed from the stereotaxic device and placed on
a separate heating pad, and the anesthetic reversal agent atipamezole
(1 mg/kg, s.c.), warm saline (2 cc, i.p.), enrofloxacin (2.5 mg/kg, s.c.)
and buprenorphine (0.1 mg/kg, s.c.) were administered. Animals
were closely monitored during recovery and, when fully awake, were
placed in clean cages with water and nutritional supplements (Nutri-
Cal and Froot Loops) available on or near the cage floor so that access
would require minimal neck movement. Saline, antibiotics, and analge-
sia were continued for 3 days. Physiological evaluations were con-
ducted 3 weeks after surgery.
Analytical Procedures
Glucose, insulin, cholesterol, triglycerides, nonesterified fatty acids,
and leptin were assayed as described (Bernal-Mizrachi et al., 2002).
Glucose and insulin tolerance tests were performed as described in
procedures separated by at least 1 week (Marshall et al., 1999).
Body composition was determined by dual-energy X-ray absorptiom-
etry. Twenty-four hour urine collections for urinary sodium and cate-
cholamines were as described (Bernal-Mizrachi et al., 2003). Renin ac-
tivity was measured in 500 ml aliquots of pooled plasma from ten
animals per condition by radioimmunoassay of in vitro-generated an-
giotensin I using a kit from DiaSorin. Electron microscopy was per-
formed by the Washington University Cell Biology & Physiology Core
with tissue prepared as described (Han et al., 2004).
Hyperinsulinemic-Euglycemic Clamps
Clamp experiments were performed essentially as described (Marshall
et al., 1999). [3-3H]glucose was infused to steady state, regular human
insulin was infused at 10 mU/kg/min, and 25% D-glucose was infused
to maintain blood glucose at 120 mg/dl for at least 90 min. The
[3-3H]glucose infusion was continued during the clamp, with labeled
glucose included in the 25% D-glucose infusion to match blood-
specific activity at steady state. The rate of appearance of glucose
(Ra), equal to the rate of glucose utilization (Rd) at steady state, was de-
termined by dividing the infusion rate of labeled glucose by the specific
activity. Endogenous glucose production was calculated by subtract-
ing the cold glucose infusion rate from the clamp Rd.
Adenovirus Treatment
AdPPARa (containing the mouse Ppara cDNA) was generated and ad-
ministered as described (Tordjman et al., 2002; Bernal-Mizrachi et al.,
2003). Viruses were infused at a dose of 63 109 pfu in a total volume of
200 ml. Expression in tissues, almost exclusively limited to liver, was
determined in a subset of animals sacrificed 3 days following infusion
by RT-PCR using RNA from aorta, liver, kidney, heart, skeletal muscle,
lung, and gonadal fat pad. The primers used were as follows: Ppara100 Cell Metabolism 5, 91–102, February 2007 ª2007 Elsevierforward, 50-TCGGCCTGGCCTTCTAAACA-30, Ppara reverse, 50-GTT
ACACCCTCCAGAACAGT-30; L32 forward, 50-TAAGCGAAACTGGCG
GAAAC-30, L32 reverse, 50-TCATTTTCTTCGCTGCGTAGC-30.
Blood Pressure
Noninvasive determinations of systolic and diastolic blood pressure
were made over several days in conscious mice using a Kent Scientific
tail-cuff system as described (Bernal-Mizrachi et al., 2002). For mice
treated with adenoviruses, measurements began 4 days following
the injection. Noninvasive results were confirmed using a PowerLab/
8SP invasive monitoring instrument (AD Instruments).
Semiquantitative RT-PCR-Based Gene Expression
Analyses were done in a GeneAmp 7700 Sequence Detector (Applied
Biosystems) using the following oligonucleotides: Ppara forward,
50-ACTACGGAGTTCACGCATGTG-30, Ppara reverse, 50-TTGTCGTA
CACCAGCTTCAGC-30, probe, 50-AGGCTGTAAGGGCTTCTTTCGGC
G-30; Ppargc1 forward, 50-CGGAAATCATATCCAACCAG-30, Ppargc1
reverse, 50-TGAGGACCGCTAGCAAGTTTG-30, probe, 50-TCATTCTC
TTCATCTACTTTCTCAAATATGTTC-30; Aco forward, 50-GGATGGTA
GTCCGGAGAACA-30, Aco reverse, 50-AGTCTGGATCGTTCAGAAT
CAAG-30, probe, 50-TCTCGATTTCTCGACGGCGCCG-30; Mcad for-
ward, 50GGAAATGATCAACAAAAAAAGTATTT-30, Mcad reverse, 50-
ATGGCCGCCACATCAGA-30, probe, 50-TGTCACACAGTAAGCACAC
ATCATTGGCTG-30; L32 forward, 50-AAGCGAAACTGGCGGAAAC-
30, L32 reverse, 50-GATCTGGCCCTTGAACCTTCT-30, probe, 50-CAG
AGGCATTGACAACAGGGTGCG-30. Results were normalized to the
housekeeping gene L32, whose expression was unaffected by geno-
type or Dex treatment.
PEPCK Enzyme Activity
10% (w/v) liver homogenates were prepared at 0C in 250 mmol/l su-
crose, 5 mmol/l HEPES (pH 7.4) buffer and centrifuged at 36003 g for
10 min. Supernatant fractions were further centrifuged at 130,000 3 g
for 30 min, and PEPCK enzyme activity was assayed by following the
consumption of NADH as previously described (Petrescu et al., 1979;
Jamieson et al., 1999).
Supplemental Data
Supplemental Data include three tables and three figures and can be
found with this article online at http://www.cellmetabolism.org/cgi/
content/full/5/2/91/DC1/.
ACKNOWLEDGMENTS
This work was supported by NIH grants P50 HL083762, HL58427,
AG20091, Clinical Nutrition Research Unit DK56341, and Diabetes
Research and Training Center DK20579. C.B.-M. was supported by
an American Diabetes Association Mentor-Based Postdoctoral Fel-
lowship. We thank Marilyn A. Levy for electron microscopy services.
Received: November 8, 2005
Revised: August 23, 2006
Accepted: December 20, 2006
Published: February 6, 2007
REFERENCES
Bellinger, L.L., and Williams, F.E. (1981). The effects of liver denerva-
tion on food and water intake in the rat. Physiol. Behav. 26, 663–671.
Benthem, L., Keizer, K., Wiegman, C.H., de Boer, S.F., Strubbe, J.H.,
Steffens, A.B., Kuipers, F., and Scheurink, A.J. (2000). Excess portal
venous long-chain fatty acids induce syndrome X via HPA axis and
sympathetic activation. Am. J. Physiol. Endocrinol. Metab. 279,
E1286–E1293.
Berger, J., and Moller, D.E. (2002). The mechanisms of action of
PPARs. Annu. Rev. Med. 53, 409–435.Inc.
Cell Metabolism
Vagally Mediated Insulin ResistanceBernal-Mizrachi, C., Weng, S., Li, B., Nolte, L.A., Feng, C., Coleman,
T., Holloszy, J.O., and Semenkovich, C.F. (2002). Respiratory uncou-
pling lowers blood pressure through a leptin-dependent mechanism
in genetically obese mice. Arterioscler. Thromb. Vasc. Biol. 22, 961–
968.
Bernal-Mizrachi, C., Weng, S., Feng, C., Finck, B.N., Knutsen, R.H.,
Leone, T.C., Coleman, T., Mecham, R.P., Kelly, D.P., and Semenko-
vich, C.F. (2003). Dexamethasone induction of hypertension and dia-
betes is PPAR-alpha dependent in LDL receptor-null mice. Nat.
Med. 9, 1069–1075.
Berthoud, H.-R., and Neuhuber, W.L. (2000). Functional and chemical
anatomy of the afferent vagal system. Auton. Neurosci. 85, 1–17.
Berthoud, H.-R., Kressel, M., and Neuhuber, W.L. (1992). An antero-
grade tracing study of the vagal innervation of rat liver, portal vein
and biliary system. Anat. Embryol. (Berl.) 186, 431–442.
Borovikova, L.V., Ivanova, S., Zhang, M., Yang, H., Botchkina, G.I.,
Watkins, L.R., Wang, H., Abumrad, N., Eaton, J.W., and Tracey, K.J.
(2000). Vagus nerve stimulation attenuates the systemic inflammatory
response to endotoxin. Nature 405, 458–462.
Cardin, S., Walmsley, K., Neal, D.W., Williams, P.E., and Cherrington,
A.D. (2002). Involvement of the vagus nerves in the regulation of basal
hepatic glucose production in conscious dogs. Am. J. Physiol. Endo-
crinol. Metab. 283, E958–E964.
Chakravarthy, M., Pan, Z., Zhu, Y., Tordjman, K., Schneider, J., Cole-
man, T., Turk, J., and Semenkovich, C.F. (2005). ‘‘New’’ hepatic fat ac-
tivates PPARa to maintain glucose, lipid and cholesterol homeostasis.
Cell Metab. 1, 309–322.
Grekin, R.J., Vollmer, A.P., and Sider, R.S. (1995). Pressor effects of
portal venous oleate infusion. A proposed mechanism for obesity hy-
pertension. Hypertension 26, 193–198.
Grekin, R.J., Dumont, C.J., Vollmer, A.P., Watts, S.W., and Webb, R.C.
(1997). Mechanisms in the pressor effects of hepatic portal venous
fatty acid infusion. Am. J. Physiol. Regul. Integr. Comp. Physiol. 273,
R324–R330.
Guerre-Millo, M., Rouault, C., Poulain, P., Andre, J., Poitout, V., Peters,
J.M., Gonzalez, F.J., Fruchart, J.C., Reach, G., and Staels, B. (2001).
PPAR-alpha-null mice are protected from high-fat diet-induced insulin
resistance. Diabetes 50, 2809–2814.
Han, D.-H., Nolte, L.A., Ju, J.-S., Coleman, T., Holloszy, J.O., and
Semenkovich, C.F. (2004). UCP-mediated energy depletion in skeletal
muscle increases glucose transport despite lipid accumulation and
mitochondrial dysfunction. Am. J. Physiol. Endocrinol. Metab. 286,
E347–E353.
Jamieson, P.M., Nyirenda, M.J., Walker, B.R., Chapman, K.E., and
Seckl, J.R. (1999). Interactions between oestradiol and glucocorticoid
regulatory effects on liver-specific glucocorticoid-inducible genes:
possible evidence for a role of hepatic 11beta-hydroxysteroid dehy-
drogenase type 1. J. Endocrinol. 160, 103–109.
Kersten, S., Seydoux, J., Peters, J.M., Gonzalez, F.J., Desvergne, B.,
and Wahli, W. (1999). Peroxisome proliferator-activated receptor alpha
mediates the adaptive response to fasting. J. Clin. Invest. 103, 1489–
1498.
Koo, S.H., Satoh, H., Herzig, S., Lee, C.H., Hedrick, S., Kulkarni, R.,
Evans, R.M., Olefsky, J., and Montminy, M. (2004). PGC-1 promotes
insulin resistance in liver through PPAR-alpha-dependent induction
of TRB-3. Nat. Med. 10, 530–534.
Lam, T.K., Pocai, A., Gutierrez-Juarez, R., Obici, S., Bryan, J., Aguilar-
Bryan, L., Schwartz, G.J., and Rossetti, L. (2005). Hypothalamic sens-
ing of circulating fatty acids is required for glucose homeostasis. Nat.
Med. 11, 320–327.
Lee, S.S., Pineau, T., Drago, J., Lee, E.J., Owens, J.W., Kroetz, D.L.,
Fernandez-Salguero, P.M., Westphal, H., and Gonzalez, F.J. (1995).
Targeted disruption of the alpha isoform of the peroxisome prolifera-
tor-activated receptor gene in mice results in abolishment of the pleio-Cell Mtropic effects of peroxisome proliferators. Mol. Cell. Biol. 15, 3012–
3022.
Lemberger, T., Staels, B., Saladin, R., Desvergne, B., Auwerx, J., and
Wahli, W. (1994). Regulation of the peroxisome proliferator-activated
receptor alpha gene by glucocorticoids. J. Biol. Chem. 269, 24527–
24530.
Lemberger, T., Saladin, R., Vazquez, M., Assimacopoulos, F., Staels,
B., Desvergne, B., Wahli, W., and Auwerx, J. (1996). Expression of
the peroxisome proliferator-activated receptor alpha gene is stimu-
lated by stress and follows a diurnal rhythm. J. Biol. Chem. 271,
1764–1769.
Magni, F., and Carobi, C. (1983). The afferent and preganglionic para-
sympathetic innervation of the rat liver, demonstrated by the retro-
grade transport of horseradish peroxidase. J. Auton. Nerv. Syst. 8,
237–260.
Marshall, B.A., Tordjman, K., Host, H.H., Ensor, N.J., Kwon, G.,
Marshall, C.A., Coleman, T., McDaniel, M.L., and Semenkovich, C.F.
(1999). Relative hypoglycemia and hyperinsulinemia in mice with
heterozygous lipoprotein lipase (LPL) deficiency. Islet LPL regulates in-
sulin secretion. J. Biol. Chem. 274, 27426–27432.
Masuzaki, H., Paterson, J., Shinyama, H., Morton, N.M., Mullins, J.J.,
Seckl, J.R., and Flier, J.S. (2001). A transgenic model of visceral obe-
sity and the metabolic syndrome. Science 294, 2166–2170.
Matsuhisa, M., Yamasaki, Y., Shiba, Y., Nakahara, I., Kuroda, A.,
Tomita, T., Iida, M., Ikeda, M., Kajimoto, Y., Kubota, M., and Hori, M.
(2000). Important role of the hepatic vagus nerve in glucose uptake
and production by the liver. Metabolism 49, 11–16.
Moreno, S., Farioli-Vecchioli, S., and Ceru, M.P. (2004). Immunolocal-
ization of peroxisome proliferator-activated receptors and retinoid X
receptors in the adult rat CNS. Neuroscience 123, 131–145.
Nahas, Z., Marangell, L.B., Husain, M.M., Rush, A.J., Sackeim, H.A.,
Lisanby, S.H., Martinez, J.M., and George, M.S. (2005). Two-year out-
come of vagus nerve stimulation (VNS) for treatment of major depres-
sive episodes. J. Clin. Psychiatry 66, 1097–1104.
Obici, S., Zhang, B.B., Karkanias, G., and Rossetti, L. (2002). Hypotha-
lamic insulin signaling is required for inhibition of glucose production.
Nat. Med. 12, 1376–1382.
Paterson, J.M., Morton, N.M., Fievet, C., Kenyon, C.J., Holmes, M.C.,
Staels, B., Seckl, J.R., and Mullins, J.J. (2004). Metabolic syndrome
without obesity: Hepatic overexpression of 11beta-hydroxysteroid
dehydrogenase type 1 in transgenic mice. Proc. Natl. Acad. Sci.
USA 101, 7088–7093.
Patsouris, D., Mandard, S., Voshol, P.J., Escher, P., Tan, N.S., Ha-
vekes, L.M., Koenig, W., Marz, W., Tafuri, S., Wahli, W., et al. (2004).
PPARalpha governs glycerol metabolism. J. Clin. Invest. 114, 94–103.
Peitl, B., Dobronte, R., Nemeth, J., Mezey, G., Kovacs, P., Paragh, G.,
and Szilvassy, Z. (2005). The prandial insulin sensitivity-modifying ef-
fect of vagal stimulation in rats. Metabolism 54, 579–583.
Petrescu, I., Bojan, O., Saied, M., Barzu, O., Schmidt, F., and Kuhnle,
H.F. (1979). Determination of phosphoenolpyruvate carboxykinase ac-
tivity with deoxyguanosine 50-diphosphate as nucleotide substrate.
Anal. Biochem. 96, 279–281.
Randich, A., Spraggins, D.S., Cox, J.E., Meller, S.T., and Kelm, G.R.
(2001). Jejunal or portal vein infusions of lipids increase hepatic vagal
afferent activity. Neuroreport 12, 3101–3105.
Reddy, J.K. (2001). Nonalcoholic steatosis and steatohepatitis. III.
Peroxisomal beta-oxidation, PPAR alpha, and steatohepatitis. Am. J.
Physiol. Gastrointest. Liver Physiol. 281, G1333–G1339.
Rodriguez, J.C., Gil-Gomez, G., Hegardt, F.G., and Haro, D. (1994).
Peroxisome proliferator-activated receptor mediates induction of the
mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase gene by fatty
acids. J. Biol. Chem. 269, 18767–18772.etabolism 5, 91–102, February 2007 ª2007 Elsevier Inc. 101
Cell Metabolism
Vagally Mediated Insulin ResistanceSmith, G.P., and Jerome, C. (1983). Effects of total and selective ab-
dominal vagotomies on water intake in rats. J. Auton. Nerv. Syst. 9,
259–271.
Subramanian, S., DeRosa, M.A., Bernal-Mizrachi, C., Laffely, N.,
Cade, W.T., Yarasheski, K.E., Cryer, P.E., and Semenkovich, C.F.
(2006). PPARa activation elevates blood pressure and does not correct
glucocorticoid-induced insulin resistance in humans. Am. J. Physiol.
Endocrinol. Metab. 291, E1365–E1371.
Tordjman, K., Bernal-Mizrachi, C., Zemany, L., Weng, S., Feng, C.,
Zhang, F., Leone, T.C., Coleman, T., Kelly, D.P., and Semenkovich,
C.F. (2001). PPARa deficiency reduces insulin resistance and athero-
sclerosis in apoE-null mice. J. Clin. Invest. 107, 1025–1034.
Tordjman, K., Standley, K., Bernal-Mizrachi, C., Leone, T., Coleman,
T., Kelly, D.P., and Semenkovich, C.F. (2002). PPARa suppresses in-
sulin secretion and induces UCP2 in insulinoma cells. J. Lipid Res.
43, 936–943.
Uno, K., Katagiri, H., Yamada, T., Ishigaki, Y., Ogihara, T., Imai, J.,
Hasegawa, Y., Gao, J., Kaneko, K., Iwasaki, H., et al. (2006). Neuronal
pathway from the liver modulates energy expenditure and systemic in-
sulin sensitivity. Science 312, 1656–1659.
Uthman, B.M., Reichl, A.M., Dean, J.C., Eisenschenk, S., Gilmore, R.,
Reid, S., Roper, S.N., and Wilder, B.J. (2004). Effectiveness of vagus
nerve stimulation in epilepsy patients: a 12-year observation. Neurol-
ogy 63, 1124–1126.102 Cell Metabolism 5, 91–102, February 2007 ª2007 Elsevier IWada, M., Connolly, C.C., Tarumi, C., Neal, D.W., and Cherrington,
A.D. (1995). Hepatic denervation does not significantly change the re-
sponse of the liver to glucagon in conscious dogs. Am. J. Physiol. 268,
E194–E203.
Walker, B.R., Sang, K.S., Williams, B.C., and Edwards, C.R. (1994).
Direct and indirect effects of carbenoxolone on responses to gluco-
corticoids and noradrenaline in rat aorta. J. Hypertens. 12, 33–39.
Wallerath, T., Witte, K., Schafer, S.C., Schwarz, P.M., Prellwitz, W.,
Wohlfart, P., Kleinert, H., Lehr, H.A., Lemmer, B., and Forstermann,
U. (1999). Down-regulation of the expression of endothelial NO syn-
thase is likely to contribute to glucocorticoid-mediated hypertension.
Proc. Natl. Acad. Sci. USA 96, 13357–13362.
Walls, E.K., Wang, F.B., Holst, M.C., Phillips, R.J., Voreis, J.S., Perkins,
A.R., Pollard, L.E., and Powley, T.L. (1995). Selective vagal rhizoto-
mies: a new dorsal surgical approach used for intestinal deafferenta-
tions. Am. J. Physiol. Regul. Integr. Comp. Physiol. 269, 1279–1288.
Whitworth, J.A., Coghlan, J.P., Denton, D.A., Graham, W.F., Humph-
ery, T.J., and Scoggins, B.A. (1979). Comparison of the effects of
‘glucocorticoid’ and ‘mineralocortocoid’ infusions on blood pressure
in sheep. Clin. Exp. Hypertens. 1, 649–663.
Xie, H., and Lautt, W.W. (1996). Insulin resistance caused by hepatic
cholinergic interruption and reversed by acetylcholine administration.
Am. J. Physiol. 271, E587–E592.nc.
